Loading…
Employees: 901
Size Shenzhen Weiguang Biological Products (002880.SZ) is a China Health Care company (Biotechnology) with a market value of $682M, the 3125th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥20.05 on 6 Nov 2026.
Performance Over six months the shares fell 22.0%, against -22.4% for the median peer and -16.4% for the China market (cap-weighted) — 10th highest of 19 in its peer set.
Growth Revenue fell 0.4% over the last twelve months (peer median +18.6%); the operating margin is 17.9% (peer median -111.2%).
Valuation It trades at 20.7× forward earnings against a peer median of 52.4× (2nd cheapest of 5).
Capital Return on invested capital runs 2.1 points above its cost of capital (5.3% WACC).
Next results Next results expected around 28 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.13B | CN¥1.26B | CN¥1.20B | CN¥1.04B | CN¥665M |
| Revenue growth | — | +5% | +15% | +57% | — |
| Gross profit | CN¥502M | CN¥468M | CN¥480M | CN¥413M | CN¥225M |
| EBITDA | n/a | CN¥445M | CN¥439M | CN¥328M | CN¥176M |
| Net income | CN¥170M | CN¥246M | CN¥254M | CN¥219M | CN¥118M |
| Free cash flow | -CN¥69.4M | CN¥108M | -CN¥75.6M | CN¥69.1M | -CN¥325M |
| Capital expenditure | CN¥108M | CN¥170M | CN¥256M | CN¥329M | CN¥327M |
| Total debt | CN¥833M | CN¥864M | CN¥697M | CN¥525M | CN¥547M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 002880.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -8.0% | -12.5% | 8th highest of 21 |
| 6-month return | -22.0% | -22.4% | 10th highest of 19 |
| Distance from 52-week high | -40.7% | -46.6% | 8th highest of 21 |
| Revenue growth (TTM) | -0.4% | +18.6% | 5th lowest of 14 |
| Operating margin | 17.9% | -111.2% | 2nd highest of 15 |
| Forward P/E | 20.7× | 52.4× | 2nd cheapest of 5 |
| ROIC minus cost of capital | +2.1 pp | -46.5 pp | 2nd highest of 10 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shenzhen Weiguang Biological Products 002880.SZ | China | $682M | -22% | 0% | 18% | 20.7× | n/a | n/a |
| Aura Biosciences AURA | United States | $680M | -22% | n/a | n/a | n/a | n/a | n/a |
| 4D Molecular Therapeutics FDMT | United States | $677M | +21% | +278,712% | -214% | n/a | n/a | n/a |
| Anhui Huaheng Biotechnology 688639.SS | China | $688M | -40% | +7% | 3% | 25.4× | n/a | n/a |
| Candel Therapeutics CADL | United States | $670M | +5% | n/a | n/a | n/a | n/a | n/a |
| Attovia Therapeutics ATTO | United States | $697M | +744% | n/a | -4,975% | n/a | n/a | n/a |
| Boji Medical Technology 300404.SZ | China | $664M | +7% | +32% | 4% | 82.0× | 35.4% | +27.2% |
| Wave Life Sciences WVE | United States | $664M | -53% | -35% | -321% | n/a | n/a | n/a |
| Solid Biosciences SLDB | United States | $707M | -9% | n/a | n/a | n/a | n/a | n/a |
| Sana Biotechnology SANA | United States | $709M | -32% | n/a | n/a | n/a | n/a | n/a |
| Getein Biotech 603387.SS | China | $647M | -12% | +8% | 21% | n/a | -8.3% | -1.3% |
| Kura Oncology KURA | United States | $647M | -23% | -7% | -412% | n/a | n/a | n/a |
| Shouyao Holdings Beijing 688197.SS | China | $726M | -16% | +4,564% | -92% | n/a | n/a | n/a |
| Design Therapeutics DSGN | United States | $639M | -28% | n/a | n/a | n/a | n/a | n/a |
| Geron GERN | United States | $636M | -29% | +19% | -8% | 16.7× | n/a | n/a |
| Apnimed APMD | United States | $629M | n/a | +380% | -140% | n/a | n/a | n/a |
| Frontier Biotechnologies 688221.SS | China | $746M | -37% | +153% | -20% | n/a | 43.2% | +21.5% |
| Ascletis Pharma 1672.HK | Hong Kong | $610M | -73% | -59% | -71,976% | n/a | n/a | n/a |
| Shaanxi Micot Pharmaceutical Technology 2335.HK | Hong Kong | $777M | n/a | n/a | n/a | n/a | n/a | n/a |
| Alphamab Oncology 9966.HK | Hong Kong | $777M | -39% | -32% | -38% | n/a | n/a | n/a |
| Genfit GNFT.PA | France | $593M | +19% | +28% | -130% | 79.3× | 40.0% | +143.5% |